In this free webinar, gain insights into adapting endpoints for the needs of rare disease trials. Attendees will also learn strategies for conducting tailored rater training and targeted data quality monitoring. The featured speaker will also describe ways to evaluate clinical meaningfulness of trial results.
TORONTO, Jan. 17, 2024 /PRNewswire-PRWeb/ -- Adapting Endpoints, Ensuring Data Quality and Determining Clinical Meaningfulness of Trial Results
Testing new therapeutic candidates in patients with rare diseases presents considerable challenges for clinical trial teams. Among these are proper endpoint selection, adaptation of endpoints for rare indications, data quality assurance practices (rater training and monitoring) and determining clinical meaningfulness of positive trial results.
In this webinar, Dr. Pam Ventola will share methodological approaches for adapting endpoints for rare disease trials. Specifically, she will outline how sponsors may adapt both standardized endpoints — such as the Vineland-3 — as well as common clinician reported outcomes — such as the clinical global impression – severity/improvement scale (CGI-S/I) — to meet the unique needs of patient populations.
In addition, Dr. Ventola will discuss rater training approaches and targeted data quality monitoring methodologies specific to rare disease trials. These processes are vital for trial success, as rare disease studies have unique challenges in the realm of rater training. In these trials, sponsors typically need to recruit patients from broad geographic areas. This means raters have varied levels of experience and expertise, opening the door for rater variance and errors.
Lastly, determining the clinical meaningfulness of trial results is a critical step in designing trials and interpreting results. Dr. Ventola will outline approaches for supporting the clinical meaningfulness of results in rare disease trials.
Register for this webinar to discover invaluable strategies to effectively navigate rare disease trials, enhancing endpoint adaptation, data quality and clinical interpretation.
Join Pam Ventola, PhD, Chief Science Officer, Cogstate, for the live webinar on Thursday, February 8, 2024, at 11am EST (4pm GMT/UK).
For more information, or to register for this event, visit Strategic Design Decisions in Rare Disease Trials.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article